DE69839326T2 - ZUSAMMENSETZUNGEN UND METHODEN ZUR MODULIERUNG DER ZELLULÄREN AKTIVITÄT VON NF-kappaB - Google Patents

ZUSAMMENSETZUNGEN UND METHODEN ZUR MODULIERUNG DER ZELLULÄREN AKTIVITÄT VON NF-kappaB Download PDF

Info

Publication number
DE69839326T2
DE69839326T2 DE69839326T DE69839326T DE69839326T2 DE 69839326 T2 DE69839326 T2 DE 69839326T2 DE 69839326 T DE69839326 T DE 69839326T DE 69839326 T DE69839326 T DE 69839326T DE 69839326 T2 DE69839326 T2 DE 69839326T2
Authority
DE
Germany
Prior art keywords
seq
agent
iκbα
ubiquitination
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839326T
Other languages
German (de)
English (en)
Other versions
DE69839326D1 (de
Inventor
Anthony San Diego MANNING
Frank Del Mar MERCURIO
Irit Alkalay
Yinon Ben-Neriah
Aaron Ciechanover
Avraham Yaron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Signal Pharmaceuticals LLC
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem, Signal Pharmaceuticals LLC filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Application granted granted Critical
Publication of DE69839326D1 publication Critical patent/DE69839326D1/de
Publication of DE69839326T2 publication Critical patent/DE69839326T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Mobile Radio Communication Systems (AREA)
DE69839326T 1997-02-18 1998-02-18 ZUSAMMENSETZUNGEN UND METHODEN ZUR MODULIERUNG DER ZELLULÄREN AKTIVITÄT VON NF-kappaB Expired - Lifetime DE69839326T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/802,322 US5932425A (en) 1997-02-18 1997-02-18 Compositions and methods for modulating cellular NF-κB activation
US802322 1997-02-18
PCT/US1998/003163 WO1998036070A1 (en) 1997-02-18 1998-02-18 COMPOSITIONS AND METHODS FOR MODULATING CELLULAR NF-λB ACTIVATION

Publications (2)

Publication Number Publication Date
DE69839326D1 DE69839326D1 (de) 2008-05-15
DE69839326T2 true DE69839326T2 (de) 2009-04-16

Family

ID=25183386

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839326T Expired - Lifetime DE69839326T2 (de) 1997-02-18 1998-02-18 ZUSAMMENSETZUNGEN UND METHODEN ZUR MODULIERUNG DER ZELLULÄREN AKTIVITÄT VON NF-kappaB

Country Status (8)

Country Link
US (1) US5932425A (https=)
EP (1) EP1009824B1 (https=)
JP (2) JP4560616B2 (https=)
AT (1) ATE391177T1 (https=)
AU (1) AU6659198A (https=)
CA (1) CA2281920C (https=)
DE (1) DE69839326T2 (https=)
WO (1) WO1998036070A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0920518A1 (en) * 1996-08-26 1999-06-09 Signal Pharmaceuticals, Inc. Stimulus-inducible i (kappa)b kinase ikk] signalsome
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
DE69739663D1 (de) 1996-12-31 2009-12-31 Antioxidant Pharmaceuticals Co Pharmazeutische glutathionpräparate und methoden zu dern verabreichung
WO1999066065A2 (en) * 1998-06-13 1999-12-23 Zarpex Biosciences Limited Proteasomal activity
ES2361660T3 (es) 1998-12-10 2011-06-21 Signal Pharmaceuticals Llc Ubicutina-ligasa e3 humana para la modulación de nk-kappa b.
US6630312B2 (en) 1999-08-10 2003-10-07 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
US6468755B1 (en) 1999-08-10 2002-10-22 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
FR2801902B1 (fr) * 1999-12-01 2005-03-04 Centre Nat Rech Scient Procedes de criblages fonctionnels d'agents aptes a moduler l'activite des complexes ubiquitine-ligases scf et leurs applications
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030044852A1 (en) * 2000-08-10 2003-03-06 Joslin Diabetes Center, Inc., A Massachusetts Corporation Methods for treatment of insulin resistance
US20060287337A1 (en) * 2001-11-09 2006-12-21 Proteologics, Inc. Trans-golgi network-associated processes, methods and compositions related thereto
AU2002349784A1 (en) * 2001-12-03 2003-06-17 Asahi Kasei Pharma Corporation Nf-kappab activating genes
FR2859733A1 (fr) * 2003-09-15 2005-03-18 Centre Nat Rech Scient Procede de criblage fonctionnel d'agents aptes a moduler l'activite des ubiquitine hydrolases et leurs applications
HUE034446T2 (en) * 2004-03-02 2018-02-28 Procter & Gamble Method for binding high internal phase emulsions (HIPE)
FR2867783B1 (fr) * 2004-03-16 2008-02-01 Cytomics Systems Procede de criblage d'agent modulant l'ubiquitination de la proteine ikbalpha et moyens destines a la mise en oeuvre dudit procede
US20070060537A1 (en) * 2005-04-28 2007-03-15 Proteologics, Inc. Methods and compositions for inhibiting viral infections
US20100292306A1 (en) * 2005-05-24 2010-11-18 Carlson C George Compositions And Methods For The Treatment Of Muscular Dystrophy
US20070202593A1 (en) * 2006-02-27 2007-08-30 Research Development Foundation Cell-Targeted IKB and Methods for the Use Thereof
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
WO2010044892A1 (en) * 2008-10-17 2010-04-22 President And Fellows Of Harvard College Diagnostic method based on large scale identification of post-translational modification of proteins
US20110082145A1 (en) * 2009-10-01 2011-04-07 Alcon Research, Ltd. Olopatadine compositions and uses thereof
NZ777336A (en) 2018-12-28 2026-02-27 Regeneron Pharma Treatment of respiratory disorders with arachidonate 15-lipoxygenase (alox15) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122463A (en) * 1990-05-17 1992-06-16 Massachusetts Institute Of Technology Methods for trans-destabilization of specific proteins in vivo and dna molecules useful therefor
EP0905236A1 (en) * 1992-10-29 1999-03-31 Medical Research Council Transcription factor DP-1
DE4243770A1 (de) * 1992-12-23 1994-06-30 Behringwerke Ag Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung
IL114615A0 (en) * 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
JPH11509085A (ja) * 1995-06-23 1999-08-17 テュラリク インコーポレイテッド インターロイキン−１レセプター関連プロテインキナーゼ及び検定
EP0920518A1 (en) * 1996-08-26 1999-06-09 Signal Pharmaceuticals, Inc. Stimulus-inducible i (kappa)b kinase ikk] signalsome

Also Published As

Publication number Publication date
EP1009824B1 (en) 2008-04-02
JP4560616B2 (ja) 2010-10-13
AU6659198A (en) 1998-09-08
WO1998036070A1 (en) 1998-08-20
JP2001512319A (ja) 2001-08-21
US5932425A (en) 1999-08-03
CA2281920C (en) 2010-05-04
CA2281920A1 (en) 1998-08-20
JP2010063461A (ja) 2010-03-25
ATE391177T1 (de) 2008-04-15
DE69839326D1 (de) 2008-05-15
HK1028784A1 (en) 2001-03-02
EP1009824A1 (en) 2000-06-21

Similar Documents

Publication Publication Date Title
DE69839326T2 (de) ZUSAMMENSETZUNGEN UND METHODEN ZUR MODULIERUNG DER ZELLULÄREN AKTIVITÄT VON NF-kappaB
EP1027440B2 (de) Inhibitor-protein des wnt-signalwegs
EP0207956B1 (de) Hirudin-pa und dessen derivate, verfahren zu deren herstellung und deren verwendung
DE69931929T2 (de) Peptidantagonisten von zonulin und methoden zu deren verwendung
DE69736351T4 (de) Methoden und mittel zur hemmung der cdk4-aktivität
DE69533255T2 (de) ISOLIERTES p27 PROTEIN UND NUKLEINSÄURE DAFÜR KODIEREND
DE69432231T2 (de) Peptide mit antithrombotischer aktivität und verfahren zu ihrer herstellung
EP0151246A2 (de) Neue Polypeptide mit alpha-Amylase-hemmender Wirkung, Verfahren zu deren Herstellung, deren Verwendung und pharmazeutische Präparate
DE60122873T2 (de) Therapeutische porenbildende peptide
DE60124532T2 (de) Neue polypeptide aus bienengift und verfahren zu deren verwendung
DE3855078T2 (de) Verfahren zur herstellung von cystatin-c oder abwandlungen davon und dns-sequenz zur ausführung dieser methode
EP0870024A2 (de) Nukleinsäuresequenzen von genen der high mobility group proteine sowie verwendungen derselben
DE60222265T2 (de) Zelltod-induktoren für mastzellen
DE60318749T2 (de) Paralytisches peptid von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
WO2001034640A2 (de) Humanes zirkulierendes virus inhibierendes peptid (virip) und seine verwendung
WO2006000213A2 (de) Peptide zur inhibition der interaktion von proteinkinase a und proteinkinase a-ankerproteinen
EP1023445B1 (de) Cadherin derived growth factor und seine verwendung
DE19957689A1 (de) Proteaseresistenter Tumorsuppressor p14(ARF)
DE69814148T2 (de) Zielspezifische abgabe zum nukleus mittels protein h von streptococcus
DE10006887A1 (de) Verbindungen, die die Aktivität oder die Konzentration des Regulatorproteins RS1 verändern
EP1499636A2 (de) Neurotrophe und neuroprotektive peptide
DE10351627B4 (de) Modulation der Angiogenese durch Bartonella henselae
WO2002095011A2 (de) Inaktivierung von genen des mep-wegs
EP0840789B1 (de) Transketolase-verwandtes protein
DE19527129A1 (de) Arzneimittel enthaltend wenigstens einen Teil des UL84-Proteins des Cytomegalovirus, Verwendung von Polypeptiden entsprechend der Aminosäuresequenz des UL84-Proteins und Verfahren zur Einführung von UL84 in Zielzellen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition